Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181235 | 1.00 | ACE (0.41) | ACEPREPCHRM3PEPD | |
| SCHEMBL30975227 | 0.83 | DPP4 (0.48) | ACE | |
| SCHEMBL7333354 | 0.77 | LMNA (0.41) | ACE | |
| SCHEMBL247604 | 0.77 | LMNA (0.41) | ACE | |
| SCHEMBL2036130 | 0.77 | LMNA (0.41) | ACE | |
| SCHEMBL27922142 | 0.76 | RAB9A (0.44) | PREPPEPD | |
| SCHEMBL28211348 | 0.76 | ACE (0.43) | ACE | |
| SCHEMBL11644333 | 0.75 | LMNA (0.40) | ACE | |
| SCHEMBL3739768 | 0.72 | ACE (0.44) | ACE | |
| SCHEMBL3721142 | 0.72 | ACE (0.44) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816406-B2 | Quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7652134-B2 | Tumor suppression agents with reduced side effects; anticancer; antibacterial and antiviral; contacting the corresponding ester with an amine and a Lewis acid | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1802306-A2 | QUINOLONE ANALOG AS CELL PROLIFERATION INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074089-A1 | Quinolone analogs | SENHWA BIOSCIENCES, INC. (TW) | 2006-04-06 | — | — | US | disclosed |
| WO-2006034113-A2 | QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063761-A1 | Novel benzothiazole compounds and methods of use thereof | SENHWA BIOSCIENCES, INC. (TW) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063761-A1 | Novel benzothiazole compounds and methods of use thereof | MLNR, CCKBR, CYP2B6 | ACE 3569/4885PREP 4249/4885CHRM3 362/4885 |
| US-20060074089-A1 | Quinolone analogs | NQO2, BAX, MCL1 | ACE 2536/4885PREP 1788/4885CHRM3 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.